Evaluating the role of FDG-PET/CT in managing infective endocarditis
Impact of FDG-PET/CT on Management of Patients with Native Valve Infective Endocarditis
This study is testing whether FDG-PET/CT imaging can help doctors make better treatment decisions for adults suspected of having infective endocarditis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 97 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Montreal Heart Institute Academic / other |
| Locations | 6 sites (Montreal, Quebec and 5 other locations) |
| Trial ID | NCT04792281 on ClinicalTrials.gov |
What this trial studies
This multicentric observational study aims to assess the impact of FDG-PET/CT imaging on the management of patients suspected of having native valve infective endocarditis (NVE). Participants will be recruited from six different healthcare centers, including two specialized cardiac centers and four tertiary care hospitals. The study will focus on patients classified as having possible infective endocarditis according to the modified Duke criteria and will evaluate how FDG-PET/CT influences clinical decision-making. The study will include adults who can provide informed consent and tolerate the PET/CT procedure.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are suspected of having native valve infective endocarditis and are referred for FDG-PET/CT imaging.
Not a fit: Patients with prosthetic cardiac valves, those who are pregnant or breastfeeding, and individuals with a body mass index over 45 kg/m2 may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the diagnostic accuracy and management strategies for patients with infective endocarditis.
How similar studies have performed: While the use of FDG-PET/CT in this context is gaining interest, this specific approach is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or older, capable to provide informed consent; * Referred for a FDG-PET/CT study * Classified as having Possible IE prior to FDG-PET/CT imaging; * Patients must be able to tolerate the physical/logistical requirements of a PET/CT scan. Exclusion Criteria: * Subjects with prosthetic cardiac valve and/or CIED; * Pregnant or breastfeeding female; * Body mass index \> 45 kg/m2.
Where this trial is running
Montreal, Quebec and 5 other locations
- Centre Hospitalier de l'Universite de Montreal — Montreal, Quebec, Canada (Not_yet_recruiting)
- Montreal Heart Institute — Montreal, Quebec, Canada (Recruiting)
- Jewish General Hospital — Montreal, Quebec, Canada (Recruiting)
- McGill University Health Center — Montreal, Quebec, Canada (Not_yet_recruiting)
- University Institute of Cardiology and Respirology of Quebec — Québec, Quebec, Canada (Not_yet_recruiting)
- Centre Hospitalier de l'Universite de Sherbrooke — Sherbrooke, Quebec, Canada (Not_yet_recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.